Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been fully informed about the study and have voluntarily agreed to take part by signing a consent form
• People whose pancreatic cancer has been confirmed by laboratory tissue or cell testing, and whose cancer cannot be surgically removed, has spread to nearby areas, or has spread to other parts of the body
• People aged between 18 and 75 years old (inclusive)
• People who have not previously received any systemic treatment for advanced pancreatic cancer
• People who have a good general performance level — able to carry out normal daily activities with at most mild limitations (ECOG score of 0 or 1)
• People who have at least one measurable tumour that meets specific size requirements on a CT scan
• People whose life expectancy is estimated to be at least 3 months
• People whose blood counts, liver function, and kidney function meet specific levels set by the trial (confirm with trial site for exact values)
• Women who are able to become pregnant and who are using effective contraception
• People who are willing and able to attend follow-up appointments and follow study instructions

Who may not be able to join:

• People who are unable or unwilling to follow the study rules and procedures
• People who have previously been treated with a type of drug called a VEGFR inhibitor, or who have previously received immune checkpoint inhibitor (ICI) therapy
• People who are currently in, or have taken part in, another drug clinical trial within the past 4 weeks
• People who have received blood transfusions, blood products, or blood cell growth-stimulating treatments (such as albumin or G-CSF) within the past 14 days
• People who have had internal radiation therapy (radioactive seed implantation) within the past 60 days
• People who have received other cancer treatments — such as chemotherapy, hormone therapy, or immunotherapy — within the past 4 weeks
• People who have had surgery or an invasive procedure within the past 4 weeks (minor procedures like IV line placement may be exceptions — confirm with trial site)
• People who have had major surgery within the past 60 days, or whose surgical wound has not fully healed
• People who have had local tumour treatments to the liver (such as embolisation, freezing, or radiofrequency ablation) within the past 4 weeks
• People who currently have high blood pressure that is not controlled by medication (systolic at or above 140 mmHg and/or diastolic at or above 90 mmHg)
• People whose urine tests show a significant level of protein
• People whose fluid build-up in the abdomen (ascites) cannot be controlled with standard treatments
• People with significant abnormalities in their blood electrolyte (salt and mineral) levels, as judged by the treating doctor
• People in whom cancer has spread to half or more of their liver, as assessed by the treating doctor
• People with significant heart conditions, including heart attack within the past 6 months, severe chest pain, bypass surgery, moderate-to-severe heart failure, certain heart rhythm problems, or reduced heart pumping function
• People who have had a serious bleeding event (Grade 3 or higher) within the past 4 weeks
• People who have had significant bleeding episodes within the past 3 months, or who have coughed up blood within the past 4 weeks, or who have had a blood clot, stroke, or mini-stroke within the past 12 months
• People with abnormal blood clotting test results, or who are currently taking blood-thinning medication
• People with poorly controlled diabetes despite standard treatment
• People with a condition that prevents them from absorbing or swallowing oral medication, including the trial drug surufatinib
• People with an active or poorly controlled serious infection
• People known to have HIV infection
• People with a known significant liver disease, including active hepatitis B or C infection, or liver cirrhosis
• People who currently have, or have a history of, cancer that has spread to the brain
• People who currently have active stomach or bowel ulcers, ulcerative colitis, bleeding from an unremoved tumour, or other conditions that could lead to bowel bleeding or perforation
• People who still have unresolved side effects above a mild level from previous cancer treatments (with some exceptions — confirm with trial site)
• People with a known or suspected allergy to the trial drug or drugs in the same group
• Women who are pregnant or breastfeeding
• People with substance use issues, or medical, psychological, or social conditions that could affect participation or results
• People who have another active cancer that has not been treated, with limited exceptions (such as certain early-stage or previously fully treated cancers — confirm with trial site)
• People whom the treating doctor considers unsuitable for the trial for any other reason

Important: Always verify eligibility with the trial site directly before applying.